116 related articles for article (PubMed ID: 15102544)
1. Genetically defined hyperlipidemia.
Smit JW; Diamant M
Pharmacogenomics; 2004 Apr; 5(3):295-304. PubMed ID: 15102544
[TBL] [Abstract][Full Text] [Related]
2. [Dyslipoproteinemia of diabetes: fibrates or statins?].
Moulin P
Diabetes Metab; 1999 Sep; 25(3):270-4. PubMed ID: 10499198
[No Abstract] [Full Text] [Related]
3. [Pharma clinics. Drug of the month. Acipimox (Olbetam)].
Scheen AJ
Rev Med Liege; 1995 Nov; 50(11):489-90. PubMed ID: 8532997
[No Abstract] [Full Text] [Related]
4. [Hyperlipidemia in hemodialysis patients].
Nishikawa O; Mune M; Yukawa S
Nihon Rinsho; 2001 Mar; 59 Suppl 3():753-7. PubMed ID: 11347168
[No Abstract] [Full Text] [Related]
5. The significance of genetic polymorphisms in modulating the response to lipid-lowering drugs.
Hoffmann MM; Winkelmann BR; Wieland H; März W
Pharmacogenomics; 2001 May; 2(2):107-21. PubMed ID: 11368750
[TBL] [Abstract][Full Text] [Related]
6. [Drug therapy of hyperlipidemia].
Kajiyama G; Horiuchi I
Nihon Rinsho; 1990 Nov; 48(11):2620-8. PubMed ID: 2270030
[No Abstract] [Full Text] [Related]
7. Hyperlipidemia. What to do when life-style changes aren't enough.
Peters WL
Postgrad Med; 1991 Oct; 90(5):213-7, 220-4. PubMed ID: 1924009
[TBL] [Abstract][Full Text] [Related]
8. [Hyperlipidemias].
Windler E; Beil FU; Greten H
Internist (Berl); 1991 May; 32(5):W37-48. PubMed ID: 1869397
[No Abstract] [Full Text] [Related]
9. Drug treatment of dyslipoproteinemia.
Larsen ML; Illingworth DR
Med Clin North Am; 1994 Jan; 78(1):225-45. PubMed ID: 8283933
[TBL] [Abstract][Full Text] [Related]
10. Triglyceride levels, pancreatitis and choice of lipid-modifying therapy.
Preiss D
Expert Rev Gastroenterol Hepatol; 2013 Mar; 7(3):193-5. PubMed ID: 23445227
[No Abstract] [Full Text] [Related]
11. [Pharmacotherapy of hyperlipoproteinemias: indications, mechanisms of action, effectiveness and side effects].
Schernthaner G; Woschnagg H
Wien Med Wochenschr; 1990 Feb; 140(3):64-75. PubMed ID: 2180212
[TBL] [Abstract][Full Text] [Related]
12. [Classification of hyperlipoproteinemias and interpretation of laboratory parameters].
Herrmann W; Lackner KJ; Schmitz G
Wien Med Wochenschr; 1994; 144(12-13):292-9. PubMed ID: 8650932
[TBL] [Abstract][Full Text] [Related]
13. [The status quo of pharmacotherapy of lipid metabolism disorders in the aged].
Reuter VW
Z Alternsforsch; 1988; 43(1):43-6. PubMed ID: 3281379
[TBL] [Abstract][Full Text] [Related]
14. Management of hyperlipidemia: goals for the prevention of atherosclerosis.
Illingworth DR
Clin Invest Med; 1990 Aug; 13(4):211-8. PubMed ID: 2208837
[TBL] [Abstract][Full Text] [Related]
15. [When statins alone are insufficient for lowering lipid levels. Efficacy and risks of lipid lowering combination therapies, in particular, that of statin-fibrate combination].
Otto C; Schwandt P
Internist (Berl); 1999 Dec; 40(12):1338-45. PubMed ID: 10642924
[No Abstract] [Full Text] [Related]
16. [Classification of disorders of lipid metabolism].
Richter WO; Schwandt P
Internist (Berl); 1992 Nov; 33(11):728-31. PubMed ID: 1478827
[No Abstract] [Full Text] [Related]
17. [Anti-hyperlipidemic drug].
Nakaya N
Nihon Rinsho; 1999 Jul; 57(7):1570-6. PubMed ID: 10429459
[TBL] [Abstract][Full Text] [Related]
18. Practical drug therapy for common hyperlipidaemias.
Tikkanen MJ
Baillieres Clin Endocrinol Metab; 1990 Dec; 4(4):719-42. PubMed ID: 2082904
[No Abstract] [Full Text] [Related]
19. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.
Oki JC
Pharmacotherapy; 1995; 15(3):317-37. PubMed ID: 7667166
[TBL] [Abstract][Full Text] [Related]
20. [MTP inhibitors and ACAT inhibitors. An update].
Ohashi K
Nihon Rinsho; 2002 May; 60(5):975-83. PubMed ID: 12030002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
